Developmental Medicine and Child Neurology
Introduction: The effects of incobotulinumtoxinA on upper limb (UL) spasticity-related pain (SRP) over multiple treatment cycles (ICs) in children/adolescents (C/As) with cerebral palsy (CP) were analyzed using pooled data from two prospective phase 3 trials.
Patients and methods: C/As aged 2–17 years with CP-associated UL spasticity received incobotulinumtoxinA for 4 ICs. SRP was assessed with the Questionnaire on Pain caused by Spasticity (QPS) using C/A- (direct or via interviewer) and parent/caregiver (P/C)-completed UL modules. The pain population included all C/As with a key QPS item score >0 at baseline; post-baseline scores of 0 indicated complete pain relief.
Results: Data from 155 C/As and 444 P/Cs with data for at least one key QPS item were included. UL general SRP was reported by 69 C/As at baseline; 39.7%/41.8% of patients treated with incobotulinumtoxinA were pain-free by week 4 of IC1/IC4 (p
Conclusion: In addition to muscle tone regulation, incobotulinumtoxinA provided sustained pain relief across multiple ICs for children with CP and UL SRP, even when they were engaged in demanding tasks.
Heinen F, Bonfert M, Kanovsky P, Schroeder AS, Chambers H, Dabrowski E, et al. Improvements in upper limb spasticity-related pain in children/adolescents with cerebral palsy after incobotulinumtoxinA injections. Dev Med Child Neurol. 2022 May;64(Suppl 3):90. doi:10.1111/dmcn.15215.